Drug Database
SI

simvastatin + triflusal (IRIST stent)

✓ Approved

Palau Pharma · HMGCR · Small Molecule

What is simvastatin + triflusal?

simvastatin + triflusal is a small molecule developed by Palau Pharma. It is approved for therapeutic indications via surgical implantation.

Drug Profile

Brand NamesIRIST stent
CompanyPalau Pharma
Drug ClassSmall Molecule
Molecular TargetHMGCR, PDE4A, PDE4B, PDE4C, PDE4D, PTGS1, PTGS2
RouteSurgical Implantation
StatusApproved
Sources: ClinicalTrials.gov, Palau Pharma

Mechanism of Action

Molecular Targets

simvastatin + triflusal acts on 7 molecular targets:

HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, MYPLG)
PDE4Aphosphodiesterase 4A (PDE4, DPDE2)
PDE4Bphosphodiesterase 4B (PDEIVB, DPDE4)
PDE4Cphosphodiesterase 4C (DPDE1, PDE21)
PDE4Dphosphodiesterase 4D (PDE43, STRK1)
PTGS1prostaglandin-endoperoxide synthase 1 (PCOX1, COX3)
PTGS2prostaglandin-endoperoxide synthase 2 (PHS-2, GRIPGHS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

simvastatin + triflusal is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Injury, poisoning and procedural complicationsRestenosis✓ Approved

Related Research Articles

PubMedFrontiers in pediatrics2026-07-17

Case Report: Successful topical simvastatin therapy in a 2-year-old girl with keratin 16-associated palmoplantar epidermal differentiation disorder.

Zhong Qingmei Q, Zhang Ying Y, Feng Zhen Z, Zhang Jinyan J et al.

Palmoplantar epidermal differentiation disorder associated with pachyonychia congenita is a rare autosomal dominant genodermatosis characterized by painful palmoplantar hyperkeratosis and nail dystrophy. Treatment options remain limited, particularly in young children, in whom systemic therapies carry safety concerns. Herein, we report a 2-year-old girl who presented with palmoplantar hyperkeratosis since 1 month of age, with progressive nail dystrophy involving all 20 nails. Whole-exome sequencing identified a hemizygous multi-exon deletion in keratin 16 (ClinVar: SUB16259296; OMIM: #167200), and orthogonal validation using amplicon-based high-throughput sequencing confirmed a 437-nucleotide deletion predicted to result in a frameshift with premature termination codon (PTC). American College of Medical Genetics and Genomics classification supported likely pathogenicity. Twice-daily application of topical 2.5% simvastatin/cholesterol cream for 11 weeks produced substantial improvement in plantar hyperkeratosis, resolution of painful fissures, and visibly improved morphology of nascent nail growth. No local or systemic adverse effects were observed. This case provides preliminary evidence that topical simvastatin may be an effective and well-tolerated therapy for keratin 16-associated palmoplantar epidermal differentiation disorder in young children, and highlights the potential importance of topical drug delivery in achieving therapeutic efficacy for this genetic subtype.

PMID 42465212
Read full article →
PubMedInternational journal of biological macromolecules2026-07-17

Intestinal stent with polydopamine-enhanced sodium alginate/polyacrylamide hydrogel coating: Design, fabrication and anti-migration performance evaluation.

Su Zekun Z, Hou Wenyun W, Wang Xuhui X, Gao Guoqing G et al.

Endoscopic stent placement is an established effective intervention for relieving acute malignant obstruction secondary to colorectal tumors. However, clinically used stents are frequently associated with complications such as tumor ingrowth and stent migration, which limit their long-term efficacy. In this study, we developed a novel 3D-printed flexible tubular intestinal stent coated with polydopamine-enhanced sodium alginate/polyacrylamide (SA/PAM) hydrogel (hereafter referred to as PSP hydrogel). The stent itself acts as a physical barrier to inhibit tumor ingrowth, whereas the PSP coated hydrogel markedly improves tissue adhesion, thereby enhancing the overall performance of the stent system. The modified hydrogel demonstrates excellent compressive strength (>45 kPa) and superior tissue adhesiveness (>10 kPa), along with stable binding to the stent surface. The coated stent exhibits sufficient flexibility and can expand effectively to restore patency in constricted intestinal segments upon deployment. Compared with uncoated stents, the hydrogel-coated version shows a significantly higher anti-migration force (>7 N) and a markedly reduced migration distance (<1 mm). These findings indicate that the viscous PSP hydrogel-coated intestinal stent holds promising potential for clinical application in the management of acute colorectal obstructions.

PMID 42463095
Read full article →
PubMedJACC. Case reports2026-07-17

IVUS-Guided Salvage of Acute Venous Stent Fracture at Compression Site in May-Thurner Syndrome.

Kumar Devesh D, Rao Shrividya S, Choudhary Anil Kumar AK, Kumar Ravi R et al.

May-Thurner syndrome results from chronic compression of the left common iliac vein between the right common iliac artery and the lumbar vertebrae. It predisposes to iliofemoral deep-vein thrombosis. A 40-year-old man presented with recurrent ulceration of the left medial gaiter region. Computed tomography venography revealed compression of the left common iliac vein. Endovascular therapy was performed and a dedicated venous stent was deployed. Postdilatation of the stent resulted in fracture of the stent at the compression point. Rescue was achieved by deploying an overlapping venous stent, restoring circular luminal geometry. The patient experienced symptomatic improvement, and the venous ulcer resolved within 5 months. This report illustrates a rare complication of venous stenting and emphasizes the critical role of intravascular ultrasound in recognizing device failure and guiding immediate corrective intervention. May-Thurner syndrome should be suspected in young patients with severe unilateral chronic venous disease. Fracture of venous stents may occur at the iliac compression site after deployment.

PMID 42467041
Read full article →
PubMedCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026-07-17

Patterns of Neoatherosclerotic Plaque Complications in Patients With Stent Failure: An Optical Coherence Tomography Study.

Incesu Gunduz G, Karadag Bilgehan B, Temiz Mahmut Kaan MK, Incesu Isil Firdevs Saribay IFS et al.

Neoatherosclerosis is a major mechanism of late and very late stent failure. While plaque rupture (PR) has traditionally been considered the dominant substrate, the prevalence and characteristics of other neoatherosclerotic plaque complications remain insufficiently defined. We aimed to investigate the morphological and clinical differences between neoatherosclerotic PR and plaque erosion (PE) using optical coherence tomography (OCT). This retrospective single-center study included patients with stent failure undergoing OCT-guided percutaneous coronary intervention between January 2020 and December 2025. Patients with neoatherosclerosis-related stent failure were classified according to OCT findings as PR or PE. Clinical presentation, angiographic characteristics, OCT-derived plaque morphology, and long-term outcomes were compared. Among 103 screened patients, 44 met the inclusion criteria; 28 had PR, 14 had PE and 2 had instent eruptive calcific nodule. PR patients more frequently presented with STEMI and demonstrated significantly higher levels of macrophage infiltration (57.1% vs. 23.1%, p = 0.043), cholesterol crystals (60.7% vs. 28.6%, p = 0.050), lipid arc ≥ 180° (80% vs. 42.9%, p = 0.031), and thin-cap fibroatheroma (35.7% vs. 7.1%, p = 0.048). In contrast, layered plaque was markedly more prevalent in PE (92.9% vs. 48.3%, p = 0.004), and minimal in-stent lumen area was smaller in PE lesions (p = 0.039). Postprocedural thrombus protrusion was significantly more common in PR (81% vs. 27.5%, p = 0.005). Although not statistically significant, all-cause and cardiac mortality were numerically higher in PR patients during follow-up. Neoatherosclerotic PR and PE represent distinct mechanisms of stent failure with different inflammatory profiles, plaque morphology, and clinical presentations. PR is associated with higher lipid burden and inflammatory activity, whereas PE is characterized by layered neointima and lower inflammatory features. OCT-based plaque characterization may improve risk stratification and support personalized treatment strategies in late stent failure.

PMID 42464582
Read full article →
PubMedAnnali italiani di chirurgia2026-07-17

Single Stent-Assisted Coiling for the Treatment of Complex, Acute-Angled Wide-Necked Intracranial Bifurcation Aneurysms Using the Bulging Technique with the Neuroform Atlas Stent.

Ni Heng H, Gu Xin X, Yin Congguo C, Xia Wenqing W et al.

Protecting both bifurcation branches with a single device is challenging when the neck of an intracranial aneurysm is centered at a bifurcation and forms an acute angle. This study aimed to evaluate the efficacy of the bulging technique using a single Neuroform Atlas stent to protect two branches in complex, acute-angled, wide-necked bifurcation aneurysms (WNBAs). We retrospectively reviewed patients with complex, acute-angled WNBAs who underwent single stent-assisted coiling using the bulging technique with a Neuroform Atlas stent between August 2020 and July 2024. Technical feasibility, procedure-related complications, and angiographic and functional outcomes were evaluated. A total of 52 eligible patients were enrolled, including 22 (42.3%) with acutely ruptured aneurysms. The bulging technique was successfully implemented in all cases. Initial angiographic assessment demonstrated complete occlusion in 33 (63.5%) cases, neck remnants in 14 (26.9%) cases, and residual aneurysms in 5 (9.6%) cases. Angiographic follow-up was available for 48 (92.3%) patients, with a median follow-up duration of 6.4 months. Follow-up angiography demonstrated complete occlusion in 42 (87.5%) patients and neck remnants in 6 (12.5%) patients. Procedure-related complications occurred in 2 (3.8%) patients and consisted of ischemic events. Favorable functional outcomes (modified Rankin Scale score, 0-2) were achieved in 48 (92.3%) patients during follow-up. No cases of permanent procedure-related morbidity or mortality were observed. The bulging technique using a single Neuroform Atlas stent appears to be a feasible and safe treatment for complex, acute-angled WNBAs, with satisfactory short-term angiographic and clinical outcomes. However, further studies with longer follow-up durations are warranted to establish its long-term efficacy.

PMID 42464824
Read full article →
PubMedBMC urology2026-07-17

Two versus four weeks ureteral stenting prior to flexible ureteroscopy after failed primary ureteral access sheath insertion: a randomized trial.

Salman Baher B, Badawy Atef A, El-Shazly Mohamed M, Alorabi Ammar A et al.

During Flexible ureteroscopy; Failed primary placement of the ureteral access sheath (UAS) or backloading of flexible ureteroscopy occurred in up to 22% of patients who required ureteric stent insertion for some time. This study was conducted to compare the outcomes of two versus four weeks of preoperative ureteral stenting in patients with failed primary ureteral access undergoing flexible ureteroscopy (FURS). This single-blind, randomized controlled trial included 60 patients with upper and/or renal stones < 20 mm who had failed primary access during FURS between April 2024 and October 2025. Patients were randomized into 2 groups to insert a ureteral double-J stent for either 2 weeks (n = 30) or 4 weeks (n = 30) before the definite FURS. The primary endpoint was successful insertion of a 10/12 Fr ureteral access sheath (UAS). Secondary outcomes included stone-free rate (SFR) (assessed by a postoperative 4-week CTUT), operative time, complications, and stent-related symptoms (assessed by the Ureteral Stent Symptom Questionnaire (USSQ)). Baseline demographic and clinical characteristics were comparable between groups. Successful UAS insertion was achieved in 90% of the 2-week group and 93.3% of the 4-week group with no difference between groups (p = 0.64). No significant differences were found between groups regarding postoperative 4-week NCCT SFR (80.0% vs. 73.3%, p = 0.54), operative time (55 vs. 48.5 min, p = 0.44), or complication rates. Ureteric injuries were minor (6.7% in each group). Stent-related symptoms measured by USSQ did not significantly differ (p = 0.24). In this randomized trial, no statistically significant differences were observed between 2-week and 4-week preoperative stenting regarding UAS insertion success, stone-free rate, operative time, or complication rates. These findings suggest that prolonging stent dwell time beyond 2 weeks may not provide a substantial additional benefit in this patient population. The trial was retrospectively registered in 12/2024 on clinicaltrials.gov under the number: NCT06761378.

PMID 42464249
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about simvastatin + triflusal